fexofenadine hydrochloride and pseudoephedrine hydrochloride
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION (fexofenadine hydrochloride and pseudoephedrine hydrochloride) by Sanofi. Approved for these symptoms due to hay fever, other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy, watery eyes ▪ itching of the nose and 4 more indications. First approved in 1997.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
ALLEGRA-D 12 HOUR is an oral extended-release tablet combining fexofenadine (a nonsedating antihistamine) and pseudoephedrine (a nasal decongestant) for relief of allergic rhinitis and upper respiratory congestion. It treats symptoms including runny nose, sneezing, itchy/watery eyes, nasal itching, throat irritation, and sinus pressure associated with hay fever and common colds. The combination addresses both allergic and congestion symptoms with a twice-daily dosing regimen.
As LOE approaches, brand teams will focus on lifecycle management, cost optimization, and transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ALLEGRA-D 12 HOUR offers limited career growth opportunity given LOE trajectory; roles are operationally focused on defending market share and managing decline rather than driving innovation. Career advancement likely requires transition to growth-stage products within the Sanofi portfolio.